Breast, Prostate, Lung, Gastrointestinal, Ovarian, Melanoma, Pancreatic Cancer, Brain Cancer, Fundamental and Translational Research, Clinical Trials
Molecular and Precision Oncology, Cancer Immunology
Breast CancerProstate CancerLung Cancer G.I. CancerOvarian CancerMelanomaPancreatic CancerBrain CancerDrug ResistanceDrug SequencingRe-purposing DrugsAdvanced Metastatic CancersIn Vitro Models3D CulturesBiomarkersLiquid BiopsyTherapeutic TargetsExosomesExtracellular Vesicles/EVsHypoxiaImmune SuppressionClinician TrialsPublic & Patient Involvement
Team/Members of the group:
Close collaborators:
Main Funders:
EU Commission H2020, Irish Research Council (Advanced Laureate Award and individual Post-Graduate awards), Enterprise Ireland, Irish Cancer Society, DAFM, Health Research Board, Breast Cancer Now, industry
Active research programmes:
Professor O Driscoll’s research group draws on academic and industry experience relating to diagnostic biomarkers and companion diagnostics for predicting patients’ response to treatment, for evaluating new drugs and new drug combinations, and re-purposing old drugs for use in cancer treatment. The group work on understanding how drug-resistance, metastasis and immune suppression occur and so might be prevented. We are very interested in advanced/metastatic cancers, as well as early disease. They have niche expertise in exosomes and other extracellular vehicles (EVs) and their DNA, RNA, and protein cargo. On a number of occasions, we have translated our bench discoveries to clinical trials.
Additional Information:
Substantial experience of work for industry to translate research for patient benefit. Very interesting in expanding this further.